<DOC>
	<DOCNO>NCT02920502</DOCNO>
	<brief_summary>Optimal Vitamin D dose obtain adequate serum concentration 25-hydroxyvitamin D ( 25OHD ) controversial . The optimal dose dose interval unknown , tendency last year give high , less frequent dos . Disease-specific dosing interest , may optimal serum concentration target base disease process . The best evidence far optimal bone health , expert agree 25OHD serum concentration 30 ng/ml . There mount evidence Vitamin D therapy reduce inflammatory response macrophage activation . The optimal dosing need decrease inflammatory response unclear , although recent mouse model demonstrate onetime high dose effective . The investigator therefore hypothesize one-time high dose cholecalciferol effective suppression macrophage production tumor necrosis factor-alpha ( TNFa ) inducible nitric oxide synthase ( iNOS ) . The purpose pilot study assess optimum dosage macrophage suppression .</brief_summary>
	<brief_title>Effect One Time Dose Cholecalciferol Serum Concentration 25-Hydroxyvitamin D Macrophages</brief_title>
	<detailed_description>3.4.1 Study Medication ( Vitamin D/Placebo ) : Patients block randomized one four group use balanced assignment . The target number patient 20 , five patient successfully complete assessment group . Groups close enrollment target reach . The recruitment continue every group reach target . The investigative pharmacy prepare dosage accord randomization hold key dose . Participants investigator blind receive cholecalciferol come 50,000 I.U . dose capsule receive placebo . Participants randomize 1 4 dos outline . All participant receive number capsule . Five participant group dose accord follow dose schema : Table 1 : Dosing Schema Cholecalciferol Dosage Group Control : 0 Cholecalciferol Capsules 4 Placebo Capsules 50,000 I.U . : 1 Cholecalciferol Capsules 3 Placebo Capsules 100,000 I.U . : 2 Cholecalciferol Capsules 2 Placebo Capsules 200,000 I.U . : 4 Cholecalciferol Capsules 0 Placebo Capsules 3.4.2 . Skin Thickness Measurement : All test site evaluate redness . Skin thickness also measure use micrometer UV exposure . 3.4.3 . MED/Sunburn Test : This procedure involve expose eight 6mm area skin increase dos simulate solar radiation ( SSR ) , rest body drape . SSR deliver 1,000-Watt xenon arc lamp , emit ultraviolet wavelength 290-400 nm , closely resemble natural sunlight . The minimal erythema dose ( MED ) determine approximately 24 hour initial exposure use chromameter record value redness associate exposed 1cm area . The overall difference MED subject assess . 3.4.4 . UVR Exposure : This procedure involve expose four 6mm area skin increase dos simulate solar radiation ( SSR ) , rest body drape . SSR deliver 1,000-Watt xenon arc lamp , emit ultraviolet wavelength 290-400 nm , closely resemble natural sunlight . The site expose dosed follow : 1 MED , 2 MED , 3 MED , 3 MED . Two site expose study , one study medication dose one study medication dose . 3.4.5 . Blood Draw : sample take venipuncture provide sample analysis serum 25OHD macrophage . - Serum 25OHD 1,25 ( OH ) : Up 6ml blood drawn measure 25OHD sent Heartland Assays , LLC . - Banked Serum : Up 30ml blood serum collect stored Dermatology research lab analyze Macrophage Harvest . - Macrophage Harvest : One-time collection 180ml whole blood process purified isolate peripheral blood macrophage Dermatology research lab . 3.4.6 . Punch Biopsy ( Tissue Sample ) : A punch biopsy removal small ( pencil eraser-sized ) circle skin use cookie cutter-like instrument . This procedure involve numb designate area skin lidocaine removal circle skin . Prior obtain punch biopsy , skin inject lidocaine , painkiller similar use dentist . Although lidocaine tingle hurt briefly numb process , volunteer feel pain punch biopsy obtain . The circle close use one five fine stitch per site , prevents bleeding , speed heal , improve appearance . The stitch remove 10-14 day later . 3.4.7 . Photographs : Photographs test site take through-out protocol . In event photograph take subject 's face identifiable feature , subject 's identity may become know . 3.5 . STUDY VISITS 3.5.1 Screening Visit - Informed Consent - Inclusion Exclusion Criteria - Medical &amp; Dermatological History - Physical Examination Vital Signs Concomitant Medications/Procedures - Blood Draw : baseline serum vitamin D level bank serum - Photographs test site MED test 3.5.2 Visit 2 : UVR # 1 - Review Inclusion Exclusion Criteria - Review Adverse Events &amp; Concomitant Medications/Procedures chromameter read - Photographs test site - Site # 1 UVR Exposure : 1 , 2 , 3 , 3 MED 3.5.3 Visit 3 : 24hours post UVR # 1 - Review Inclusion Exclusion Criteria - Review Adverse Events &amp; Concomitant Medications/Procedures - Chromameter read - Photographs test site - Skin Thickness Measurements 3.5.4 Visit 4 : 48 hour post UVR # 1 - Review Inclusion Exclusion Criteria - Review Adverse Events &amp; Concomitant Medications/Procedures chromameter read - Photographs test site - Skin Thickness Measurements - Punch Biopsy one 3 MED site # I 3.5.5 Visit 5 : 72 hour post UVR # 1 - Review lnclusion Exclusion Criteria - Review Adverse Events &amp; Concomitant Medications/Procedures chromameter read - Photographs test site - Skin Thickness Measurements 3.5.6 Visit 6:1week post UVR # 1 - Review lnclusion Exclusion Criteria - Review Adverse Events &amp; Concomitant Medications/Procedures chromameter read - Photographs test site - Skin Thickness Measurements 3.5.7 Visit 7 : UVR # 2 : 2 week post UVR # 1 - Review lnclusion Exclusion Criteria - Review Adverse Events &amp; Concomitant Medications/Procedures Photographs test site - Skin Thickness Measurements - Site # 2 UVR Exposure : I , 2 , 3 , 3 MED - One-time dose study medication ( vitamin D placebo ) , 1 hour UVR 3.5.8 Visit 8 : 24 hour post UVR # 2 - Review lnclusion Exclusion Criteria - Review Adverse Events &amp; Concomitant Medications/Procedures Chromameter read - Photographs test site - Skin Thickness Measurements - Blood Draw : Serum vitamin D level bank serum 3.5.9 Visit 9 : 48 hour post UVR # 2 - Review lnclusion Exclusion Criteria - Review Adverse Events &amp; Concomitant Medications/Procedures chromameter read - Photographs test site - Skin Thickness Measurements - Blood Draw : Serum vitamin D level bank serum - Punch Biopsy one 3 MED site # 2 3.5.10 Visit 10 : 72 hour post UVR # 2 - Review Inclusion Exclusion Criteria - Review Adverse Events &amp; Concomitant Medications/Procedures - Chromameter read - Photographs test site - Skin Thickness Measurements - Blood Draw : Serum vitamin D level bank serum 3.5.11 Visit 11 : 1 week post UVR # 2 - Review Inclusion Exclusion Criteria - Review Adverse Events &amp; Concomitant Medications/Procedures chromameter read - Photographs test site - Skin Thickness Measurements - Blood Draw : Serum vitamin D level bank serum 3.5.12 Visit 12 : 2 week post UVR # 2 - Review Inclusion Exclusion Criteria - Review Adverse Events &amp; Concomitant Medications/Procedures chromameter read - Photographs test site - Skin Thickness Measurements - Blood Draw : Serum vitamin D level bank serum 3.5.13 Visit 13 : One month post UVR # 2 - Review Inclusion Exclusion Criteria - Review Adverse Events &amp; Concomitant Medications/Procedures - Photographs test site 4 . RISKS AND DISCOMFORTS - MINIMIZED 4.1 . Study Medication ( Vitamin D/Placebo ) : Vitamin D well tolerate often used clinical practice . It freely available counter supplement . There side effect oral vitamin D , severe hypercalcemia prolong use high dose . Vitamin D toxicity occur active form give ( 1,25 dihydroxyvitamin D ) prolong exposure high dose vitamin D3 . Both young old adult take one time high dose vitamin D3 safely . It possible allergic reaction could occur medication participant ask report symptom . 4.2 . Skin Thickness Measurement : know risk evaluate measure skin 's thickness micrometer . 4.3 . Minimal Erythema Dose ( MED ) Ultraviolet Light Exposure ( UVR ) : The risk associate procedure minimal , test site expose . The consequence expose UV light short-term , primarily involve mild redness exposure site follow minor itching dryness skin several day later . The degree sunburn typically mild moderate UV dose use enough cause blister skin . 4.4 . Blood Draw : Risks blood draw may include occurrence discomfort and/or bruise site puncture , less likely , formation small clot , swell vein , bleed puncture site . 4.5 . Punch Biopsy ( Tissue Sample ) : Punch biopsy pose minimal risk , volunteer instruct proper care biopsy site . Lidocaine may cause tingle burn sensation inject skin . Potential problem localize biopsy site include bleed oozing , discomfort , infection . The biopsy site heal small , flat scar , may red several month . The scar may also turn light darker surround skin time . 4.6 . Photographs : There know risk take photograph . In event photograph take subject 's face identifying feature , patient 's identity may know .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Hydroxycholecalciferols</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Calcifediol</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Adults age 18 year old Fitzpatrick Skin Type IIll In good general health able list current medication medical condition Capable give informed consent Volunteers age 18 year young Women pregnant , nursing , may become pregnant next 3 month Participants take illegal drug Chronic medical condition Currently take statin , ketoconazole , colestipol , cholestyramine , phenobarbitol , phenytoin , mineral oil Currently consume 800 IU vitamin D day Current recent use antiinflammatory medication medication may cause photosensitivity , discretion Pl .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>